Cost-utility analysis of biologic treatments for moderate-to-severe crohn's disease

Pharmacotherapy

Volumn 32, Issue 6, 2012, Pages 515-526

  Tang, Derek H ^a   Armstrong, Edward P ^b   Lee, Jeannie K ^c  

^a Departments of Pharmaceutical Sciences   (United States)

^b Pharmacy Practice and Science   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adalimumab; Biologic treatment; Certolizumab pegol; Cost; Cost utility analysis; Crohn's disease; Decision analysis; Infliximab; Natalizumab; Utility

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; HOSPITALIZATION; HUMAN; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; UNITED STATES;

ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864585275     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01053.x     Document Type: Article

References (59)

1. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study. Gut 2004 Oct;53(10):1471-8
2. Gregor JC, McDonald JWD, Klar N, Wall R, Atkinson W, Lamba B, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3(4):265-76
3. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other western countries: A systematic review. Curr Med Res Opin 2008;24 (2):319-28
4. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in japan. J Gastroenterol 2009;44(7):659-65
5. Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted county, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13(3):254-61
6. Goh K, Xiao SD. Inflammatory bowel disease: A survey of the epidemiology in Asia. J Dig Dis 2009;10(1):1-6
7. Zvidi I, Hazazi R, Birkenfeld S, Niv Y. The prevalence of Crohn's disease in Israel: A 20-year survey. Dig Dis Sci 2009;54 (4):848-52
8. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007;25(8):861-70
9. Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn's disease: A meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16(2):347-53
10. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104(2):465-83
11. Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the united states for moderately to severely active Crohn's disease. Pharmacoeconomics 2009;27(7):609-21
12. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16(1):112-24
13. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-33
14. U.S. Food and Drug Administration. Tysabri (natalizumab): Update of healthcare professional information, 2011. Available from http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199965. htm. Accessed July 5, 2011
15. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: A cost-effectiveness analysis. Aliment Pharmacol Ther 2007;12:1509-20
16. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating united kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30(3):265-74
17. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4(8):1017-24
18. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132(1):52-65
19. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
20. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
21. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357 (3):239-50
22. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
23. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997;337(15):1029-35
24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359 (9317):1541-9
25. Humira prescribing information. North Chicago, IL: Abbott Laboratories; 2011. Available from http://www.rxabbott.com/pdf/humira.pdf. Accessed May 2011
26. Cimzia prescribing information. Smyrna, GA: UCB, Inc.; 2009. Available from http://www.cimzia.com/pdf/Prescribing-Information. pdf. Accessed May 2011
27. Remicade prescribing information. Malvern, PA: Centocor Ortho Biotech Inc.; 2011. Available from http://www.remicade. com/remicade/assets/hcp-ppi.pdf. Accessed May 2011
28. Tysabri prescribing information. Cambridge, MA: Biogen Idec Inc.; 2011. Available from http://www.tysabri.com/en-US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed May 2011
29. Disability statistics Cornell University; 2010. Available from http://www.ilr.cornell.edu/edi/disabilitystatistics/reports/acs.cfm? statistic=1. Accessed May 2011
30. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18
31. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther 2004;12:1337-46
32. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348(1):24-32
33. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. Gastroenterology 2007;132(5):1672-83
34. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126(2):402-13
35. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117 (4):761-9
36. Oxford centre for evidence-based medicine levels of evidence. Centre for Evidence Based Medicine; 2009. Available from http://www.cebm.net/index.aspx?o= 1025. Accessed May 2011
37. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17(1):1-12
38. Drugstore.com. 2011. Available from http://www.drugstore. com/. Accessed May 2011
39. DestinationRx drug compare. 2011. Available from http://www. destinationrx.com/default.aspx. Accessed May 2011
40. Jones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010;252(2):307-12
41. Agency for Healthcare Research and Quality -HCUPnet. U.S. Department of Health & Human Services; 2011. Available from http://hcupnet.ahrq.gov/. Accessed May 2011
42. Abraham M, Ahlman JT, Boudreau AJ. 2011 current procedural terminology (CPT) standard edition. 4th ed. Chicago, IL: American Medical Association Press, 2010
43. Wasserman Y. Physicians' fee reference 2011. 28th ed. Milwaukee, WI: Medical Publishers, 2011
44. Bureau of Labor Statistics. United States Department of Labor; 2011. Available from http://www.bls.gov/data/. Accessed May 2011
45. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology 2008;71(5):357-64
46. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology 2008;135 (5):1493-9
47. Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value Health 2010;13(2):188-95
48. Arias E. United states life tables, 2006. National Vital Statistics Report. Hyattsville, MD: Centers for Disease Control and Prevention, 2011
49. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117(1):49-57
50. Weterman IT, Biemond I, Pena AS. Mortality and causes of death in Crohn's disease. review of 50 years' experience in Leiden university hospital. Gut 1990;31(12):1387-90
51. Andrews HA, Lewis P, Allan RN. Mortality in Crohn's disease-a clinical analysis. Q J Med 1989;71(265):399-405
52. Grosse SD. Assessing cost-effectiveness in healthcare: History of the 50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8(2):165-78
53. Loftus EV Jr, Pan X, Zurawski P, Mulani P, Chao J. Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States. J Crohns Colitis 2011; doi:10.1016/j.crohns.2011.05.005
54. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011;45(2):113-18
55. Federal supply schedule. United States Department of Veteran Affairs; 2011. Available from http://www.pbm.va.gov/Drug-PharmaceuticalPrices.aspx. Accessed May 2011
56. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28(1):76-87
57. Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009;21(11):1302-9
58. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. Pharmacoeconomics 1997;11(5):444-53
59. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: A lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20(3):274-9.